The FDA is currently retreating into a defensive crouch. Commissioner Robert Califf is out making the rounds, defending the agency's recent string of accelerated approvals against a wall of populist outrage and academic skepticism. The narrative is predictable: critics claim the FDA has grown too cozy with "Big Pharma," lowering the bar for efficacy and letting unproven drugs hit the market just to appease shareholders.
They are wrong. In fact, they are dangerously wrong.
The "lazy consensus" suggests that a cautious FDA is a safe FDA. This mindset assumes that every month spent in additional clinical trials is a month spent protecting the public. It ignores the invisible graveyard—the thousands of patients who die while a potentially life-saving therapy sits in a bureaucratic holding pattern. When the FDA waits for perfect data, it isn't being rigorous. It is being cowardly.
The real scandal isn't that we are approving drugs too fast. It’s that we are still using a 20th-century validation model to regulate 21st-century medicine.
The Statistical Fallacy of the Precautionary Principle
Critics point to "surrogate endpoints"—markers like tumor shrinkage or protein levels—as proof of the FDA’s decline. They want to see "hard" data, like overall survival rates, before a drug is cleared. On the surface, this sounds responsible. In practice, it is a death sentence for patients with rare or aggressive diseases.
Waiting for five-year survival data in a terminal lung cancer trial means everyone in the control group is dead before the drug even reaches the pharmacy shelves. By demanding absolute certainty, we prioritize the "Type I error" (approving a drug that doesn't work) while completely ignoring the "Type II error" (failing to approve a drug that does).
I have watched biotech firms with legitimate, life-extending therapies go bankrupt because they couldn't afford the $500 million price tag of a five-year "gold standard" trial. When a company dies in the "Valley of Death," the medicine dies with it. The FDA’s move toward accelerated approval isn't a gift to corporations; it is a vital bridge for innovation.
The Myth of the Unbiased Randomized Controlled Trial
The gold standard—the Randomized Controlled Trial (RCT)—is no longer the untouchable titan it once was. In the age of precision medicine and gene therapy, the RCT is often a blunt instrument.
If you are developing a drug for a genetic mutation that affects only 500 people worldwide, how do you run a 3,000-person double-blind study? You can't. Yet the critics demand the same level of statistical significance ($p < 0.05$) that they require for a new blood pressure pill.
We need to embrace Real-World Evidence (RWE). This means monitoring how a drug performs in the wild, using electronic health records and wearable data, rather than relying solely on the artificial environment of a trial. The FDA is starting to do this, and the backlash from the "purists" is deafening. These critics would rather have a perfectly clean data set than a living patient.
Data Debt and the Cost of Certainty
Every time a regulator asks for "one more study," they are adding to the "Data Debt" of the healthcare system.
The cost to develop a single new drug is now estimated at over $2.6 billion. A massive chunk of that is spent navigating the FDA's shifting goalposts. Who pays for that? The patient. High drug prices are the direct result of a regulatory environment that values process over outcomes.
If we want cheaper drugs, we need a faster path to market. You cannot demand a decades-long, multi-billion dollar vetting process and then act shocked when the resulting pill costs $50,000 a dose.
The Aduhelm Shadow
The elephant in the room is always Aduhelm. When the FDA approved Biogen’s Alzheimer’s drug against the advice of its own committee, the gates of hell opened. It was labeled the ultimate proof of regulatory capture.
But let’s look at the nuance the critics missed. For thirty years, we have had zero progress in Alzheimer’s. The "wait and see" approach resulted in a 100% failure rate for patients. The FDA took a calculated risk to jumpstart a stagnant market. Was the drug a miracle? No. But it forced a shift in the research ecosystem that eventually led to more effective treatments like Leqembi.
Sometimes, the role of a regulator is to signal to the market that a specific therapeutic area is "open for business." Without that signal, venture capital dries up, and the labs go dark.
The Counter-Intuitive Truth About Safety
We are told that faster approvals lead to more recalls. The data doesn't back this up.
A study of FDA approvals from 1949 to 2014 found that while the speed of reviews has increased significantly since the PDUFA (Prescription Drug User Fee Act) was passed in 1992, the rate of safety-related withdrawals has remained relatively stable. We are getting better at identifying risks through post-market surveillance.
We don't need to front-load all the caution. We need to shift the burden of proof to a continuous loop. Approve early based on strong surrogate signals, but mandate rigorous, real-world follow-ups. If the drug fails to deliver in the real world, pull it.
The current system is binary: it's either "Safe" or "Unsafe." That’s a fairy tale. Every drug is a trade-off. For a mother with Stage IV glioblastoma, a 10% chance of a severe side effect is a bargain for a 20% chance of an extra year of life. The FDA’s critics want to make that choice for her. They want to protect her into an early grave.
Stop Asking if the FDA is Too Fast
The question "Is the FDA approving drugs too quickly?" is the wrong question. It assumes that "slow" equals "scientific."
The real question is: "How do we modernize the definition of proof?"
If we continue to worship the RCT at the expense of patient access, we aren't being rigorous scientists. We are being high priests of a dying religion. The Commissioner shouldn't be apologizing for accelerated approvals. He should be apologizing for the fact that it still takes twelve years to bring a molecule from the lab to the bedside.
We are currently in a technological boom—CRISPR, mRNA, AI-driven protein folding—yet we are trying to process these miracles through a regulatory sieve designed in the 1960s.
The High Cost of the Status Quo
The downside of my argument is obvious: occasionally, a drug will hit the market that doesn't work as well as we hoped. Some people might even be harmed by side effects that weren't caught in a smaller, faster trial.
That is a tragedy. But it is a visible tragedy.
The thousands of people who die because a drug was delayed by three years are an invisible tragedy. They don't get headlines. They don't get Congressional hearings. They just die.
If you are more comfortable with people dying from "natural causes" while waiting for a bureaucrat's signature than you are with a patient taking a calculated risk on a new therapy, you aren't an advocate for public health. You are an advocate for stagnation.
Stop demanding a risk-free world. It doesn't exist. Start demanding a regulatory body that values time as much as it values data. Every day the FDA spends "defending" its decisions is another day a terminal patient loses their last chance.
The FDA isn't too fast. It's still agonizingly, lethally slow.
Fire the bureaucrats. Hire more statisticians. Embrace the risk.
Anything less is just managed decline.
